The global ocular pain market is experiencing significant growth, driven by various factors such as the increasing prevalence of eye disorders, the rising geriatric population, and advancements in diagnostic technologies. Ocular pain, often associated with conditions such as dry eye, corneal abrasions, uveitis, and glaucoma, has prompted the development of innovative treatment options. The market is characterized by a variety of pharmaceuticals, including over-the-counter (OTC) medications and prescription drugs, as well as non-pharmacological treatments such as eye drops, ointments, and surgeries. The companies in the market are focusing on research and development activities to introduce innovative products and expand their market presence.
Global Ocular Pain Market size is projected to grow with a CAGR of 8% during the forecast period of 2024 to 2031.
To know more, visit https://www.databridgemarketresearch.com/de/reports/global-ocular-pain-market
Below are the Top Five Ocular Pain Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Bausch & Lomb Incorporated
|
Bausch & Lomb Incorporated is a renowned eye health company that focuses on the development, manufacturing, and marketing of eye health products. The company offers a wide range of products, including contact lenses, lens care products, pharmaceuticals, and surgical devices used in eye surgery. They offer several products aimed at providing relief from ocular pain. These products include prescription medications for conditions such as dry eye syndrome, inflammation, and infections, as well as over-the-counter eye drops and ointments for temporary relief from minor eye irritations.
|
|
North America, Middle East and Africa, Europe, South America, Asia- Pacific
|
In July 2021, Bausch & Lomb Incorporated launched Biotrue Hydration Boost Lubricant Eye Drops and Biotrue Micellar Eyelid Cleansing Wipes. These products are preservative-free and provide the best therapeutic options for dry eye. This thereby improved their revenue for the market.
|
|
2.
|
Novartis AG
|
Novartis has a strong presence in the field of eye care, offering a wide range of products for various eye conditions, including those related to ocular pain. The company's eye care portfolio includes prescription medications, over-the-counter products, and surgical devices used in the treatment of eye disorders. It offers several products aimed at providing relief from ocular pain and discomfort. These products include eye drops and ointments for conditions such as dry eye syndrome, inflammation, and infections.
|
|
Americas, Middle East and Africa, Europe, Asia- Pacific
|
In September 2018, Novartis AG won the Ophthalmology Vision Award (XOVA) 2018 for non-profit eye health initiatives. The award for presented to the company at Euretina 2018. All the award winners were planning to help create sustainable eye clinics, train professionals, and improve awareness among the rural population. This helped the company in gaining more global recognition.
|
|
3.
|
Sun Pharmaceutical Industries Ltd.
|
Sun Pharma offers a range of ophthalmic products aimed at addressing various eye conditions, including ocular pain. The company's ophthalmic portfolio includes prescription medications and over-the-counter products for the treatment of eye disorders such as dry eye syndrome, inflammation, and infections.
|
|
North America, Middle East and Africa, Europe, South America, Asia- Pacific
|
In November 2018, Sun Pharmaceutical Industries Ltd. entered into a definitive agreement to acquire Pola Pharma Inc. The acquired company is a Japanese pharmaceutical company engaged in research and development, manufacture, sale, and distribution of branded and generic products in Japan. This acquisition has enhanced the company’s footprints in Japan and has led to increased demand and sales of products in future.
|
|
4.
|
Omeros Corporation
|
Omeros Corporation has developed Omidria (phenylephrine and ketorolac injection), a medication used during cataract surgery and intraocular lens replacement to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. Omidria is the first and only FDA-approved product for this indication and is effective in clinical trials. With a strong emphasis on scientific excellence and a dedication to addressing unmet medical needs,
|
|
North America
|
In June 2021, Omeros Corporation participated in the BofA 2021 Napa BioPharma Virtual Conference. The company leaders will demonstrate their product and its application to customers, thereby gaining more global recognition.
|
|
5.
|
Akorn Operating Company LLC
|
Akorn offers a range of ophthalmic products aimed at providing relief from ocular pain and discomfort. These products include prescription medications, over-the-counter eye drops, and ointments for conditions such as dry eye syndrome, inflammation, and infections.
|
|
North America, Europe
|
In February 2021, Akorn Operating Company LLC abbreviated New Drug Application (ANDA) approval for Loteprednol Etabonate Ophthalmic Gel, 0.5%, from the U.S Food and Drug Administration FDA. This helped the company in improving their ophthalmic product portfolio.
|
Conclusion
The global ocular pain market is characterized by a diverse range of companies offering innovative products and therapies aimed at addressing various eye conditions. Key players such as Novartis AG, Bausch & Lomb Incorporated, Sun Pharmaceutical Industries Ltd., Akorn Operating Company LLC, and Omeros Corporation are actively involved in research and development to introduce novel treatments and enhance their product portfolios. The market is driven by factors such as the increasing prevalence of eye disorders, the growing geriatric population, and advancements in diagnostic technologies. These factors, coupled with the rising demand for effective and safe eye care products, are expected to drive market growth in the coming years.
